Deep Sharma1, Meredith Hawkins2, Matthew K Abramowitz3. 1. Division of Nephrology, Department of Medicine. 2. Division of Endocrinology, Department of Medicine, and. 3. Division of Nephrology, Department of Medicine, Department of Epidemiology and Population Health, Albert Einstein College of Medicine, Bronx, New York matthew.abramowitz@einstein.yu.edu.
Abstract
BACKGROUND AND OBJECTIVES: Muscle wasting is common among patients with ESRD, but little is known about differences in muscle mass in persons with CKD before the initiation of dialysis. If sarcopenia was common, it might affect the use of body mass index for diagnosing obesity in people with CKD. Because obesity may be protective in patients with CKD and ESRD, an accurate understanding of how sarcopenia affects its measurement is crucial. DESIGN, SETTING, PARTICIPANTS, & MEASUREMENTS: Differences in body composition across eGFR categories in adult participants of the National Health and Nutrition Examination Survey 1999-2004 who underwent dual-energy x-ray absorptiometry were examined. Obesity defined by dual-energy x-ray absorptiometry versus body mass index and sarcopenia as a contributor to misclassification by body mass index were examined. RESULTS: Sarcopenia and sarcopenic obesity were more prevalent among persons with lower eGFR (P trend <0.01 and P trend <0.001, respectively). After multivariable adjustment, the association of sarcopenia with eGFR was U-shaped. Stage 4 CKD was independently associated with sarcopenia among participants ≥60 years old (adjusted odds ratio, 2.58; 95% confidence interval, 1.02 to 6.51 for eGFR=15-29 compared with 60-89 ml/min per 1.73 m(2); P for interaction by age=0.02). Underestimation of obesity by body mass index compared with dual-energy x-ray absorptiometry increased with lower eGFR (P trend <0.001), was greatest among participants with eGFR=15-29 ml/min per 1.73 m(2) (71% obese by dual-energy x-ray absorptiometry versus 41% obese by body mass index), and was highly likely among obese participants with sarcopenia (97.7% misclassified as not obese by body mass index). CONCLUSIONS: Sarcopenia and sarcopenic obesity are highly prevalent among persons with CKD and contribute to poor classification of obesity by body mass index. Measurements of body composition beyond body mass index should be used whenever possible in the CKD population given this clear limitation.
BACKGROUND AND OBJECTIVES: Muscle wasting is common among patients with ESRD, but little is known about differences in muscle mass in persons with CKD before the initiation of dialysis. If sarcopenia was common, it might affect the use of body mass index for diagnosing obesity in people with CKD. Because obesity may be protective in patients with CKD and ESRD, an accurate understanding of how sarcopenia affects its measurement is crucial. DESIGN, SETTING, PARTICIPANTS, & MEASUREMENTS: Differences in body composition across eGFR categories in adult participants of the National Health and Nutrition Examination Survey 1999-2004 who underwent dual-energy x-ray absorptiometry were examined. Obesity defined by dual-energy x-ray absorptiometry versus body mass index and sarcopenia as a contributor to misclassification by body mass index were examined. RESULTS:Sarcopenia and sarcopenic obesity were more prevalent among persons with lower eGFR (P trend <0.01 and P trend <0.001, respectively). After multivariable adjustment, the association of sarcopenia with eGFR was U-shaped. Stage 4 CKD was independently associated with sarcopenia among participants ≥60 years old (adjusted odds ratio, 2.58; 95% confidence interval, 1.02 to 6.51 for eGFR=15-29 compared with 60-89 ml/min per 1.73 m(2); P for interaction by age=0.02). Underestimation of obesity by body mass index compared with dual-energy x-ray absorptiometry increased with lower eGFR (P trend <0.001), was greatest among participants with eGFR=15-29 ml/min per 1.73 m(2) (71% obese by dual-energy x-ray absorptiometry versus 41% obese by body mass index), and was highly likely among obeseparticipants with sarcopenia (97.7% misclassified as not obese by body mass index). CONCLUSIONS:Sarcopenia and sarcopenic obesity are highly prevalent among persons with CKD and contribute to poor classification of obesity by body mass index. Measurements of body composition beyond body mass index should be used whenever possible in the CKD population given this clear limitation.
Authors: Paul Muntner; Mark Woodward; Devin M Mann; Daichi Shimbo; Erin D Michos; Roger S Blumenthal; April P Carson; Haiying Chen; Donna K Arnett Journal: Hypertension Date: 2010-05-03 Impact factor: 10.190
Authors: Elisabeth Ejerblad; C Michael Fored; Per Lindblad; Jon Fryzek; Joseph K McLaughlin; Olof Nyrén Journal: J Am Soc Nephrol Date: 2006-04-26 Impact factor: 10.121
Authors: Chi-yuan Hsu; Charles E McCulloch; Carlos Iribarren; Jeanne Darbinian; Alan S Go Journal: Ann Intern Med Date: 2006-01-03 Impact factor: 25.391
Authors: William L Haskell; I-Min Lee; Russell R Pate; Kenneth E Powell; Steven N Blair; Barry A Franklin; Caroline A Macera; Gregory W Heath; Paul D Thompson; Adrian Bauman Journal: Med Sci Sports Exerc Date: 2007-08 Impact factor: 5.411
Authors: Hirokazu Honda; Abdul Rashid Qureshi; Jonas Axelsson; Olof Heimburger; Mohamed E Suliman; Peter Barany; Peter Stenvinkel; Bengt Lindholm Journal: Am J Clin Nutr Date: 2007-09 Impact factor: 7.045
Authors: Lesley A Stevens; Josef Coresh; Christopher H Schmid; Harold I Feldman; Marc Froissart; John Kusek; Jerome Rossert; Frederick Van Lente; Robert D Bruce; Yaping Lucy Zhang; Tom Greene; Andrew S Levey Journal: Am J Kidney Dis Date: 2008-03 Impact factor: 8.860
Authors: D Fouque; K Kalantar-Zadeh; J Kopple; N Cano; P Chauveau; L Cuppari; H Franch; G Guarnieri; T A Ikizler; G Kaysen; B Lindholm; Z Massy; W Mitch; E Pineda; P Stenvinkel; A Treviño-Becerra; A Trevinho-Becerra; C Wanner Journal: Kidney Int Date: 2007-12-19 Impact factor: 10.612
Authors: Andrew S Levey; Lesley A Stevens; Christopher H Schmid; Yaping Lucy Zhang; Alejandro F Castro; Harold I Feldman; John W Kusek; Paul Eggers; Frederick Van Lente; Tom Greene; Josef Coresh Journal: Ann Intern Med Date: 2009-05-05 Impact factor: 25.391
Authors: Amy J Kogon; Jennifer Roem; Michael F Schneider; Mark M Mitsnefes; Babette S Zemel; Bradley A Warady; Susan L Furth; Nancy M Rodig Journal: Pediatr Nephrol Date: 2022-08-26 Impact factor: 3.651
Authors: Sankar D Navaneethan; Jesse D Schold; Susana Arrigain; John P Kirwan; Joseph V Nally Journal: Kidney Int Date: 2016-01-12 Impact factor: 10.612
Authors: Yue Yue Zhang; Li Jie Gu; Jin Fang Bao; Wei Jie Yuan; Juan Huang; Min Chao Cai; Hong Lei Yu; Wei Zhang Journal: Eur J Clin Nutr Date: 2019-01-03 Impact factor: 4.016